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ABSTRACT
Tumor molecular profiling has enabled selection of targeted therapies in a host 
of solid tumors. Here we used a retrospective clinical cohort, to evaluate the benefit 
of tailoring treatments for female genital tract malignancy, using tumor molecular 
profiles. Clinical outcome data for 112 patients was retrospectively separated into two 
groups. These either followed a matched treatment plan that incorporated at least 
one drug recommended according to their tumor profile and none that were expected 
to have no benefit (64 patients), or was unmatched with suggested treatments 
and received at least one drug that was anticipated to lack benefit for that tumor 
(48 patients).
In the group of patients whose drugs matched those recommended by molecular 
profiling of their tumor, their overall survival was 593 days on average, compared 
to 449 days for patients that did not; removing drugs predicted to have no benefit 
from treatment regimens received after profiling increased survival by 144 days 
on average (P = 0.0265). In the matched treatment group, 30% of patients had 
died by the last time of monitoring, whereas this was 40% in the unmatched group  
(P = 0.2778). The IHC biomarker for the progesterone receptor was demonstrated 
to be prognostic for survival.
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INTRODUCTION
Cancers of the female reproductive system including 
cervical cancer, cancer of the uterus, ovary, vulva, vagina, 
and fallopian tube cause significant numbers of cancer 
deaths and morbidity worldwide. Cancer of the female 
genital tract is the third most frequently occurring type of 
malignancy in women [1].
Excluding high grade serous ovarian cancers, the 
clinical management of the gynaecological malignancies 
mentioned above remains reliant on surgery in early or 
localized disease, with radiotherapy and chemotherapy 
utilizing platinum-based regimens in locally advanced 
or metastatic disease [2–4]. The overexpression of the 
estrogen receptor (ER) and/or progesterone receptor (PR) 
in endometrial cancer has been effectively utilized in 
therapeutic strategies in metastatic disease [5–7]. However 
many cancers such as uterine carcinosarcoma, uterine and 
ovarian clear cell carcinoma, and other histologies, are 
typically lacking in targeted treatment options, despite 
recent data that indicates benefit in blocking the HIF-1/
VEGF signaling pathway [8].
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Here we used data from Caris Life Sciences to find 
if tumor molecular profiling including led to better patient 
outcomes, and the impact on drug usage.
RESULTS
Clinical data describing treatments and outcomes 
for 112 advanced stage female genital tract cancer patients 
from Caris Life Sciences was analyzed retrospectively; the 
patients were treated in a number of clinics in the USA. 
Baseline information regarding histology, staging, age and 
previous treatment was noted at time of Caris profiling 
(Tables 1 and 2, Figure 1C–see plots on the right-hand side). 
Survival from point of testing was ascertained. Patients’ 
treatment was classified as matched or unmatched. This 
depended on whether the drugs selected by the clinician 
following the date of collection for profiling were predicted 
to be beneficial from analysis of the molecular profile of the 
tumor. As shown in Table 2, endometrial cancer is the most 
prevalent type within this cohort (25%).
In Table 3, the number of patients treated with 
a drug is shown in the first column, and the number of 
continuous treatment periods is given in all other columns, 
i.e. treatments of the same patient with intervening periods 
are counted separately. The drugs given to the most 
number of patients were carboplatin and paclitaxel (93 
patients each), and cisplatin (42). The most common drugs 
received overall as measured by separate treatments were 
also carboplatin, paclitaxel, and cisplatin, and these were 
given in similar proportions in the matched and unmatched 
treatments. Patients received a very similar number of 
treatments overall whether they were in the matched or 
unmatched groups i.e. 3.53 compared to 3.62 drugs.
Including the time prior to profiling, in the matched 
group 53% of drugs given (120 treatments) were predicted 
to be beneficial, 4% (9 treatments) lacked benefit, and 
43% (97) were neither of these. In the unmatched 21% 
(37 treatments) were profiled as beneficent, 49% (85) lacked 
benefit, and 30% (52) being neither. 38% of patients in the 
unmatched subset received at least one drug proposed to be 
of benefit, and 19% received two or more beneficial drugs.
Overall carboplatin, paclitaxel and cisplatin were the 
most frequently selected cytotoxic drugs, and interestingly 
platinums were given frequently in both the matched and 
unmatched category; 45% of treatments with carboplatin 
were given to patients who were predicted not to benefit 
from the agent. When considering only treatments after 
the time of tumor profiling, these drugs were still the 
most often administered drugs in both the matched and 
unmatched groups. Some drugs that were used had no 
recommendation associated with them, and were placed 
in a neither (or neutral) category. The most common drug 
in the neutral category was paclitaxel (given for 61 time 
periods, i.e. 15% of all treatments overall for this cohort).
Biomarkers explored
The only baseline biomarker predictive of better 
outlook and improved overall survival was the PR 
overexpression (Figure 2). Differences in the IHC 
biomarkers between the matched and unmatched groups 
are also compared in Figure 1B.
Matched treatments compared to unmatched–
characteristics and outcomes
The data was divided into two groups; one whose 
treatments always matched those recommended using 
their biomarker profiles and in the other they did not. 
In the matched treatment group there were 64 patients, 
and these all received one or more recommended drugs 
after the time of collection for molecular profiling and 
concurrently none that were predicted to lack benefit 
after sample collection. In the unmatched treatment group 
there were 48 patients, and these were all given at least 
one drug that was expected to lack benefit after collection 
for profiling.
The survivals of the two groups are compared in 
waterfall plots in Figure 3, where each bar displays a 
treatment plan for an individual cancer patient. The 112 
bars in total represent the 64 matched (on the left with 
a darker grey background) and 48 unmatched patients 
(on the right with a lighter grey background), and each is 
ordered from left to right by survival time after profiling 
was performed, so that post-profiling survival time 
increases across the plot. Drugs predicted to be of benefit 
and those that lack benefit are indicated with color coded 
bands–green, red and yellow indicate drugs of benefit, lack 
of benefit and neither of these, respectively.
Patients in the matched group on average survived 
for 593 days after profiling, compared to 449 days for 
patients from the unmatched group; this is an increase of 
32% (P = 0.0265). In the matched group 30% of patients 
were deceased when monitoring finished, compared to 
40% of the unmatched group patients. Figure 1A also 
shows a Kaplan-Meier curve, where there is an increase in 
overall survival for the patients that were only treated with 
drugs expected to be beneficial.
The patients who received one or more drugs 
predicted to lack benefit had a worse overall survival 
(OS) in general than the patients who received a 
single drug that were in this category. If patients with 
endometrioid adenocarcinoma are removed, the average 
survival after monitoring is 555 days versus 431 days 
for matched versus unmatched (P = 0.0797); this might 
be because they had fewer treatment options. If instead 
the patients that received megestrol acetate or tamoxifen 
citrate are removed, survival changes to 610 days for 
matched patients and 447 days for the unmatched group 
(P = 0.0176).
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Table 1: Ages of patients in both treatment groups
Age Matched Unmatched
20–29 0 0
30–39 3 1
40–49 7 7
50–59 13 8
60–69 24 20
70–79 15 6
80–89 2 6
Table 2: Patient and tumor information for the matched and unmatched groups compared with all
Group
Patient & Tumor Information
Age Ethnicity Histology Grade Stage Survival 
(Days)
Mortality %
All patients (112) 62.7 White: 92 Endometrioid adenocarcinoma, 
NOS: 28
Grade 4/ 
Undifferentiated: 4 (4%)
IV: 28 (25%) 531 34
Black/African 
American:15
Squamous cell carcinoma, NOS: 
11
Grade 3/ Poorly 
differentiated: 72 (64%)
III no IIIC: 22 
(19%)
Asian: 2 Mixed cell adenocarcinoma: 10 Grade 2 / Moderately 
differentiated: 22 (20%)
IIIC: 16 
(14%)
Other/unknown: 1 Serous cystadenocarcinoma, 
NOS: 9
Grade 1 / Well 
differentiated: 7 (6%)
II: 12 (11%)
Hawaiian/Pacific 
Islander: 1
Adenocarcinoma, NOS: 9 Unknown / Not 
determined: 6 (5%)
I: 31 (28%)
American Indian/
Alaskan Native: 1
Carcinosarcoma, NOS: 8 None / Not applicable: 
1 (1%)
Unknown: 3 
(3%)
Papillary serous 
cystadenocarcinoma: 5
Papillary serous adenocarcinoma: 
4
Adenocarcinoma, endocervical 
type: 4
Mullerian mixed tumor: 4
Carcinoma, NOS: 3
Clear cell adenocarcinoma, 
NOS: 3
Squamous cell carcinoma, 
keratinizing, NOS: 3
Papillary adenocarcinoma, NOS: 2
Mucinous cystadenocarcinoma, 
NOS: 1
Adenosquamous carcinoma: 1
Squamous cell carcinoma, spindle 
cell: 1
Mesodermal mixed tumor: 1
Serous surface papillary 
carcinoma: 1
Adenosarcoma: 1
Clear cell adenocarcinofibroma: 1
Papillary carcinoma, NOS: 1
Adenocarcinoma, intestinal 
type: 1
Matched only (64) 62.5 White: 53 Endometrioid adenocarcinoma, 
NOS: 19
Grade 4/ 
Undifferentiated: 2 (3%)
IV: 16 (25%) 593 30
Black/African 
American: 9
Serous cystadenocarcinoma, 
NOS: 7
Grade 3/ Poorly 
differentiated: 43 (67%)
III no IIIC: 13 
(20%)
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DISCUSSION
This report analyzed a female genital 
tract malignancy cohort, that received treatment 
recommendations based on molecular profiling of 
their tumors, by Caris Life Sciences using mostly 
immunohistochemistry (IHC) indicators. Patients whose 
treatments concurred with their recommendations, were 
compared to those that did not because they received at 
least one drug that was designated by Caris as lacking 
benefit. The group of patients that matched profiling 
recommendations had an increase of 32% in survival 
compared to the unmatched set of patients, which is an 
increase of 144 days, from 449 to 593 days.
The drugs given most often for all patients were 
carboplatin (112 times), paclitaxel (110 times) and 
cisplatin (48 times). This was also true in the matched and 
unmatched subsets, whether including all treatments or 
only those after the time of profiling.
The matched and unmatched groups received 
similar numbers of treatments (3.53 vs 3.62). However, 
the unmatched subset was comprised of patients with 
shorter survival times and higher mortality rates. This 
may have been influenced by the unmatched group having 
tumors that were generally more advanced than those in 
the group of matched patients, as shown in Table 2. We 
further hypothesize that the overexpression of ERs and 
PRs in endometrial cancers in particular, has contributed 
Hawaiian/Pacific 
Islander: 1
Carcinosarcoma, NOS: 6 Grade 2 / Moderately 
differentiated: 11 (17%)
IIIC: 9 (14%)
Other/Unknown: 1 Adenocarcinoma, NOS: 4 Grade 1 / Well 
differentiated: 4 (6%)
II: 6 (9%)
Mixed cell adenocarcinoma: 4 Unknown / Not 
determined: 3 (5%)
I: 17 (27%)
Squamous cell carcinoma, NOS: 4 None / Not applicable: 
1 (2%)
Unknown: 3 
(5%)
Mullerian mixed tumor: 3
Papillary serous 
cystadenocarcinoma: 2
Adenocarcinoma, endocervical 
type: 2
Papillary adenocarcinoma, NOS: 2
Clear cell adenocarcinoma, 
NOS: 2
Carcinoma, NOS: 2
Adenocarcinoma, intestinal 
type: 1
Papillary carcinoma, NOS: 1
Clear cell adenocarcinofibroma: 1
Serous surface papillary 
carcinoma: 1
Papillary serous 
adenocarcinoma: 1
Adenosquamous carcinoma: 1
Mucinous cystadenocarcinoma, 
NOS: 1
Unmatched (48) 63.0 White: 39
Black/African 
American: 6
Asian: 2
American Indian/
Alaskan Native: 1
Endometrioid adenocarcinoma, 
NOS: 9
Squamous cell carcinoma, NOS: 7
Mixed cell adenocarcinoma: 6
Adenocarcinoma, NOS: 5
Squamous cell carcinoma, 
keratinizing, NOS: 3
Papillary serous 
cystadenocarcinoma: 3
Papillary serous adenocarcinoma: 
3
Carcinosarcoma, NOS: 2
Adenocarcinoma, endocervical 
type: 2
Serous cystadenocarcinoma, 
NOS: 2
Mullerian mixed tumor: 1
Adenosarcoma: 1
Clear cell adenocarcinoma, 
NOS: 1;
Mesodermal mixed tumor: 1
Carcinoma, NOS: 1
Squamous cell carcinoma, spindle 
cell: 1
Grade 4/ 
Undifferentiated: 2 (4%)
Grade 3/ Poorly 
differentiated: 29 (61%)
Grade 2 / Moderately 
differentiated: 11 (23%)
Grade 1 / Well 
differentiated: 3 (6%)
Unknown / Not 
determined: 3 (6%)
IV: 12 (25%)
III no IIIC: 9 
(19%)
IIIC: 7 (15%)
II: 6 (12%)
I: 14 (29%)
449 40
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to the survival difference seen in the matched versus 
unmatched cohorts. Of the 112 patients, 10 received 
megestrol or tamoxifen, and response to ER/PR directed 
therapies is likely to have improved survival in this 
matched cohort. This is perhaps reflected in the PR status 
being the only IHC biomarker that was significantly 
associated with better survival (Figure 2). In other cohorts, 
gynaecological cancers such as endometrial cancer or low 
grade ovarian cancers that overexpress ERs and PRs can 
respond to hormonal therapies [7, 9], and it has been noted 
that PR status indicates better prognosis in ovarian and 
endometrial cancers [10–13], although in cervical cancer 
the receptor status is not thought to be correlated with 
survival [14].
Although we have only identified PR as standing 
out from the other biomarkers in terms of prognostic 
ability, this does not mean that other markers used within 
the panels do not contribute in a cumulative fashion to 
influence accuracy of predictions in a more subtle but 
important way, for example, the other markers that are 
labelled in the IHC volcano plot shown in Figure 2.
This is likely to account for much of the difference 
in survival between the two cohorts. Despite this, different 
cytotoxic agents such as pemetrexed and capecitabine were 
used with benefit, as was the mTOR inhibitor temsirolimus 
in the matched cohort. This data shows that there is 
differential expression of potentially interesting biomarkers 
such as ERCC1, TS and PTEN in gynaecological cancers. 
However, no conclusions are possible regarding their effect 
on drug response given the small dataset.
Overall, although tumor molecular profiling is in 
its infancy, we find that molecular profiling results can 
be used successfully to improve treatment of female 
genital tract cancer, but that this is largely as a result of 
identification of established IHC predictors of response to 
hormonal therapy. The benefit of molecular profiling in 
gynaecological malignancies will likely continue to grow 
significantly as treatments of these tumors are increasingly 
utilizing targeted strategies such as anti-angiogenics, 
PARP inhibition, and immune modulation. More data is 
needed to validate in prospective studies the application 
of IHC and sequencing-based prognostic and predictive 
biomarkers, in gynaecological cancers.
MATERIALS AND METHODS
The Caris CODE database (Comprehensive 
Oncology Database Explorer) version 1.0 contains tumor 
molecular profile data for 841 patients with solid tumors. 
It contains demographic information about these patients, 
the drug treatments that they received before and after 
molecular profiling and their clinical outcomes. There are 
112 advanced stage female genital tract cancer patients 
described within this resource, and we mined this cohort 
after web scraping the data, to assess how much tumor 
profiling recommendations were used in drug selection 
by clinicians, and if any molecular subsets had different 
outcomes. Tables 1 and 2 describe the clinical and 
demographic characteristics of the female genital tract 
cohort that was studied here.
Figure 1: (A) Kaplan-Meier curve of the increase in overall survival for patients treated only with therapies profiled to be beneficial 
compared to patients who had one or more therapies predicted to have no benefit. (B) Biomarkers compared for tumors from the matched 
and unmatched patients; positive ratio gives the percentage that have positive biomarker results i.e. for IHC, positive is protein expression 
above a certain threshold, and for sequencing biomarkers, positive is a gene mutation that is generally expected to be pathogenic. The 
size of a circle shows the number of cases. (C) Age, treatment numbers, survival time and grade of samples compared between the two 
treatment types. Blue = matched, red = unmatched.
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The amount of time that patients were monitored 
varied, as shown in Figure 3; on average patients’ 
treatment records were available for 921 days after 
diagnosis (938 for matched treatment patients, 897 for 
unmatched), and on average the time of monitoring 
after profiling was 531 days. The longest amount of 
time that treatment records were available, i.e. before 
and after profiling up until the last day of contact, 
was 4871 days. The longest time of monitoring after 
profiling (the patient represented on the furthest right 
of Figure 1) was 1366 days which was 1440 days after 
diagnosis.
Table 3: Drugs given most often for the matched and unmatched treatment groups compared against all patients, and 
also the most common drugs that were predicted to be beneficial, lacking benefit, or neither
Number of 
Patients Treated Most Frequently Administered Drugs (Total Treatment Periods)
All patients 
treated
All patients 
– treatment 
periods
Matched only 
patients, all 
treatments
Matched, after 
profiling treatments 
only
Unmatched 
patients, all 
treatments
Unmatched, 
after profiling 
treatments 
only
Drugs 
predicted of 
benefit
Drugs 
predicted to 
lack benefit
Drugs with 
no prediction 
(neither of 
benefit or lack 
of benefit)
carboplatin; 
paclitaxel –  93 
patients
carboplatin 
(112)
carboplatin; 
paclitaxel (62)
carboplatin (34) carboplatin (50) carboplatin (23) carboplatin (51) carboplatin (31) paclitaxel (61)
- paclitaxel (110) - paclitaxel (33) paclitaxel (48) paclitaxel (20) cisplatin (23) paclitaxel (23) carboplatin 
(28)
cisplatin –  42 
patients
cisplatin (48) cisplatin (23) cisplatin (14) cisplatin (25) cisplatin (8) paclitaxel (22) cisplatin (18) bevacizumab 
(9)
doxorubicin 
hydrochloride 
–  18 patients
doxorubicin 
hydrochloride 
(20)
doxorubicin 
hydrochloride 
(12)
doxorubicin 
hydrochloride (7)
gemcitabine 
hydrochloride 
(10)
gemcitabine 
hydrochloride 
(7)
doxorubicin 
hydrochloride 
(13)
doxorubicin 
hydrochloride 
(7)
docetaxel (8)
bevacizumab; 
gemcitabine 
hydrochloride 
–  11 patients
bevacizumab; 
gemcitabine 
hydrochloride 
(14)
docetaxel (9) bevacizumab (5) bevacizumab; 
doxorubicin 
hydrochloride 
(8)
bevacizumab; 
doxorubicin 
hydrochloride 
(4)
pegylated 
liposomal 
doxorubicin 
hydrochloride 
(11)
gemcitabine 
hydrochloride 
(4)
cisplatin (7)
- - pegylated 
liposomal 
doxorubicin 
hydrochloride 
(7)
megestrol acetate; 
docetaxel (4)
- - gemcitabine 
hydrochloride 
(10)
letrozole; 
pemetrexed 
disodium; 
anastrozole (2)
patupilone (5)
pegylated 
liposomal 
doxorubicin 
hydrochloride 
–  10 patients
pegylated 
liposomal 
doxorubicin 
hydrochloride 
(11)
bevacizumab; 
topotecan 
hydrochloride 
(6)
- pemetrexed 
disodium; 
pegylated 
liposomal 
doxorubicin 
hydrochloride 
(4)
pegylated 
liposomal 
doxorubicin 
hydrochloride; 
pemetrexed 
disodium (3)
tamoxifen 
citrate (6)
- ifosfamide; 
topotecan 
hydrochloride 
(4)
docetaxel; 
topotecan 
hydrochloride 
–  9 patients
docetaxel (10) dalantercept; 
vinorelbine 
tartrate; nab-
paclitaxel; 
capecitabine; 
temsirolimus 
(2)
pegylated liposomal 
doxorubicin 
hydrochloride; 
topotecan 
hydrochloride (3)
- - megestrol 
acetate (4)
- dalantercept; 
vinorelbine 
tartrate; nab-
paclitaxel; 
capecitabine; 
temsirolimus 
(2)
- topotecan 
hydrochloride 
(9)
tamoxifen 
citrate (5)
- topotecan 
hydrochloride 
(3)
topotecan 
hydrochloride 
(2)
bevacizumab;
pemetrexed 
disodium (3)
oxaliplatin; 
docetaxel; 
irinotecan 
hydrochloride; 
topotecan 
hydrochloride; 
temozolomide 
(1)
-
tamoxifen citrate 
–  6 patients
tamoxifen 
citrate (6)
megestrol 
acetate (5)
- dalantercept (2) docetaxel; 
temsirolimus; 
dacarbazine; 
vinorelbine 
tartrate; 
ifosfamide (1)
- - -
The most commonly given drugs are listed in descending order (the number of treatments is given in parentheses).
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Figure 2: Volcano plot of biomarkers showing prognostic value for female genital tract cancer survival. The biomarker of 
significance–found on the right in green–is the IHC marker for the progesterone receptor (PR). Green circle = the hazard rate of a positive 
biomarker result is significantly lower than that of a negative biomarker result, grey circles = the difference between a positive biomarker 
result and a negative biomarker result is not significant.
Figure 3: Treatments ordered by survival time for matched and unmatched patients. Regimens followed by 64 matched 
patients in ascending survival time (after profiling) are on the left (with a darker gray background), and treatments for 48 unmatched 
patients are on the right (light gray background), also ordered by survival time. Each column corresponds to an individual patient. The 
ordinate is time (days) where zero is when molecular profiling of the patient’s tumor occurred. If a black line is present at the top of a bar 
this indicates death. Dark gray within a bar shows the time from diagnosis to either last time of monitoring or death. Green is a period 
while receiving a drug of benefit. Red is a drug designated by Caris as lacking benefit. Yellow is a combination of treatments that are both 
of benefit and lack thereof. Blue is a neutral therapy, i.e. neither benefit nor lack of benefit.
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